medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 6

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (6)


Hepatitis C and Its Metabolic Complications in Kidney Disease

Fabrizi F, Donato FM, Messa P

Idioma: Ingles.
Referencias bibliográficas: 66
Paginas: 851-861
Archivo PDF: 217.27 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kidney Disease: Improving Global Outcomes. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int 2008; 73(Suppl. 109): S1-S99.

  2. CDC. Recommendations for preventing transmission of infections among chronic haemodialysis patients. MMWR 2001; 5: 1-43.

  3. Fissell R, Bragg-Gresham J, Woods J, Jadoul M, Gillespie B, Hedderwick S, Rayner H, et al. Patterns of hepatitis C prevalence and seroconversion on haemodialysis from three continents: the DOPPS. Kidney Int 2004; 65: 2335-42.

  4. Goodkin D, Bieber B, Gillespie B, Robinson B, Jadoul M. Hepatitis C infection is very rarely treated among haemodialysis patients. Am J Nephrol2013; 38(5): 405-12.

  5. Alashek W, McIntyre C, Taal W. Hepatitis B and C infection in haemodialysis patients in Libya: prevalence, incidence and risk factors. BMC Infect Dis 2012; 12: 265.

  6. Su Y, Yan R, Duan Z, Norris J, Wang L, Jiang Y, Xing W, et al. Prevalence and risk factors of hepatitis C and B virus infections in hemodialysis patients and their spouses: a multicenter study in Beijing, China. J Med Virol 2013; 85: 425-32.

  7. Unmate I, Denue B, Kida I, Ohioma O, Baba D, Goni W. Risk factors for hepatitis C virus seropositivity among hemodialysis patients receiving care at kidney centre in a tertiary health facility in Maiduguri, Nigeria. Pan Afr Med J 2014; 19: 305.

  8. Zahran A. Prevalence of seroconversion of hepatitis C virus among hemodialysis patients in Menoufia Governorate, Egypt. Arab J Nephrol Transplant 2014; 7: 133-5.

  9. Lioussfi Z, Errami Z, Radoui A, Rhou H, Ezzaitouni F, Ouzeddoun N, Bayahia R, et al. Viral hepatitis C and B among dialysis patients at the Rabat University Hospital: prevalence and risk factors. Saudi J Kidney Dis Transpl 2014; 25: 672-9.

  10. Dumaidi K, Al-Jawabreh A. Prevalence of occult HBV among haemodialysis patients in two districts in the northern part of the West Bank, Palestine. J Med Virol 2014; 86: 1694-9.

  11. Schiller A, Timar R, Siriopol D, Timar B, Bob F, Schiller O, Drug V, et al. Hepatitis B and C virus infection in the hemodialysis population from three Romanian regions. Nephron 2015; 129: 202-8.

  12. Duong C, Olszyna D, McLaws M. Hepatitis B and C virus infections among patients with end stage renal disease in a low-resourced hemodialysis center in Vietnam: a cross-sectional study. BMC Public Health 2015; 15: 192.

  13. Vidales-Braz B, da Silva N, Lobato R, Germano F, da Mota L, Barros E, de Martinez A. Detection of hepatitis C virus in patients with terminal renal disease undergoing dialysis in southern Brazil: prevalence, risk factors, genotypes, and viral load dynamics in haemodialysis patients. J Virol 2015; 12: 8. Doi: 10.1186/s12985-015-0238-z.

  14. Aman K, Al-Dubai S, Aman R, Hawash A, Alshagga M, Kassim S. Prevalence and associated factors of hepatitis C virus infection among renal disease patients on maintenance hemodialuysis in three health centers in Aden, Yemen: a cross-sectional study. Saudi J Kidney Dis Transpl 2015; 26: 380-5.

  15. Malhotra R, Soin D, Grover P, Galhotra S, Khutan H, Kaur N. Hepatitis B virus and hepatitis C virus co-infection in haemodialysis patients: A retrospective study from a tertiary care hospital of North India. J Nat Sci Biol Med 2016; 7: 72-4.

  16. Halle M, Choukem S, Kaze F, Ashuntantang G, Tchamago V, Mbour-Djieka Y, Temfack E, et al. Hepatitis B, hepatitis C, and human immunodeficiency virus seroconversion positivity rates and their potential risk factors among patients on maintenance haemodialysis in Cameroon. Iran J Kidney Dis 2016; 10: 304-9.

  17. Hasanjani Roushan M, Farokhtabar S, Bayani M, Siadati S. Epidemiological aspects of hepatitis B and C and human immunodeficiency viruses among haemodialysis patients in Mazandaran Province, Iran. Nephrourol Mon 2016; 8: e37878.

  18. Locatelli F, de Francisco A, Deray G, Fliser D, Armstrong G, Dougherty F, Ehrhard P. Mortality and cardiovascular morbidity associated with haemoglobin levels: a pooled analysis of randomised controlled trials. Nephron Clin Pract 2014; 128: 323-32.

  19. Fabrizi F, Dixit V, Messa P. Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality ? J Viral Hepat 2012; 19: 601-7.

  20. Kalantar-Zadeh K, McAllister C, Miller L. Clinical characteristics and mortality in hepatitis C-positive haemodialysis patients: a population based study. Nephrol Dial Transplant 2005; 20: 1662-9.

  21. Scott D, Wong J, Spicer T, Dent H, Mensah F, McDonald S, Levy M. Adverse impact of hepatitis C virus infection on renal replacement therapy and renal transplant patients in Australia and New Zealand. Transplantation 2010; 90: 1165-71.

  22. Ohsawa M, Kato K, Tanno K, Itai K, Fujishima Y, Okayama A, Turin T, et al. Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver-disease-related mortality in haemodialysis patients. J Epidemiology 2011; 21: 491-9.

  23. Goodkin D, Bieber B, Jadoul M, Martin P, Kanda E, Pisoni R. Mortality, Epidemiology, hospitalization, and quality of life among haemodialysis patients with hepatitis C infection. Clin J Am Soc Nephrol 2017; 12: 287-9.

  24. Zampino R, Marrone A, Restivo L, Guerrera B, Sellitto A, Rinaldi L, Romano C, et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 5: 528-40.

  25. Adinolfi L, Zampino R, Restivo R, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014; 20: 3410-7.

  26. Mangia A, Ripoli M. Insulin resistance, steatosis and hepatitis C virus. Hepatol Int 2013; 7 (Suppl. 2): S782-S789.

  27. Voulgaris T, Sevastianos V. Atherosclerosis as extra-hepatic manifestation of chronic infection with hepatitis C virus. Hep Res Treatment 2016; 7629318.

  28. Ampuero J, Romero-Gomez M. Assessing cardiovascular risk in hepatitis C: An unmet need. World J Hepatol 2015; 8: 2214-29.

  29. Petta S, Maida M, Macaluso F, Barbara M, Licata A, Craxi A, Cammà C. Hepatitis C virus infection is associated with increased cardiovascular mortality: A meta-analysis of observational studies. Gastroenterology 2016; 150: 145-55.

  30. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: A systematic review and meta-analysis. Dig Dis Sci 2015; 60: 3801-13.

  31. Liangpunsakul S, Chalasani N. Relationship between hepatitis C and microalbuminuria: results from the NHANES III. Kidney Int 2005; 67: 285-90.

  32. Huang J, Chuang W, Dai C, Ho C, Hwang S, Chen S, Lin Z, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Intern Med 2006; 260: 255-62.

  33. Tsui J, Vittinghoff E, Shlipak M, O’Hare A. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey. J Am Soc Nephrol 2006; 17: 1168-74.

  34. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res 2008; 38: 775-83.

  35. Yanik E, Lucas G, Vkahov D, Kirk G, Mehta S. HIV and proteinuria in an injection drug user population. Clin J Am Soc Nephrol 2010; 5: 1836-43.

  36. Lee J, Lee M, Yang Y, Lu S, Chen H, Hwang S. Association of hepatitis C and B virus infection with chronic kidney disease in an endemic area in Taiwan. A cross-sectional study. Am J Kidney Dis 2010; 56: 23-31.

  37. Kurbanova N, Qayyum R. Association of hepatitis C virus infection with proteinuria and glomerular filtration rate. Clin Transl Sci 2015; 8: 421-4.

  38. Tsui J, Vittinghoff E, Shlipak M, Berthental D, Inadomi J, Rodriguez R, O’Hare A. Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease. Arch Intern Med 2007; 167: 1271-6.

  39. Moe S, Pampalone A, Ofner S, Rosenman M, Teal E, Hsiu S. Association of hepatitis C virus infection with prevalence and development of kidney disease. Am J Kidney Dis 2008; 51: 885-92.

  40. Asrani S, Buchanan P, Pinski B, Rey L, Schnitzler M, Kanwal F. Lack of association between hepatitis C infection and chronic kidney disease. Clin Gastroenterol Hepatol 2010; 8: 79-84.

  41. Dalrymple L, Koepsell T, Sampson J, Louie T, Dominitz J, Young B, Kestenbaum B. Hepatitis C virus infection and the prevalence of renal insufficiency. Clin J Am Soc Nephrol 2007; 2: 715-21.

  42. Lucas G, Jing Y, Sulkowski M, Abraham A, Estrella M, Atta M, Fine D, et al., for the NA-ACCORD of the IeDEA. Hepatitis C viremia and the risk of chronic kidney disease in HIV-infected individuals. J Infect Dis 2013; 208: 1240-9.

  43. Satapathy S, Lingisetty C, Williams S. Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infection. Hepatol Int 2012; 6: 369-78.

  44. Gilbert A, Lion G. Arterites infectieuses experimentales. C R Hebd Seances Soc Biol Fil 1889; 41 : 583-4.

  45. Stassen F, Vainas T, Bruggeman C. Infection and atherosclerosis. An alternative view on an outdated hypothesis. Pharmacol Rep 2008; 60: 85-92.

  46. Boddi M, Abbate R, Chellini B, Giusti B, Giannini C, Pratesi G, Rossi L, et al. Hepatitis C virus RNA localization in human carotid plaques. J Clin Virol 2010; 47: 72-5.

  47. Soma J, Saito T, Taguma Y, Chiba S, Sato H, Sugimura K, Ogawa S, et al. High prevalence and adverse effects of hepatitis C virus infection in type II diabetic-related nephropathy. J Am Soc Nephrol 2000; 11: 690-9.

  48. Crook E, Penumalee S, Gavini B, Filippova K. Hepatitis C is a predictor of poorer renal survival in diabetic patients. Diabetes Care 2005; 298: 2187-91.

  49. Noureddine L, Usman S, Yu Z, Moorthi R, Moe S. Hepatitis C increases the risk of progression of chronic kidney disease in patients with glomerulonephritis. Am J Nephrol 2010; 32: 311-6.

  50. Ble M, Aguilera V, Rubin A, Garcia-Eliz M, Vinaixa C, Prieto M, Berenguer M. Improved renal function in liver transplant recipients treated for hepatitis C virus with a sustained virological response and mild chronic kidney disease. Liver Transpl 2014; 20: 25-34.

  51. Bergman S, Accort N, Turner A, Glaze J. Hepatitis C infection is acquired pre-ESRD. Am J Kidney Dis 2005; 45: 684-9.

  52. Iwasa Y, Otsubo S, Sugi O, Sato K, Asamiya Y, Eguchi A, Iwasaki T, et al. Patterns in the prevalence of hepatitis C virus infection at the start of haemodialysis in Japan. Clin Exp Nephrol 2008; 12: 53-7.

  53. Tsui J, Vittinghoff E, Anastos K, Augenbraun M, Young M, Nowicki M, Cohen M, et al. Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women’s Interagency HIV Study. Am J Kidney Dis 2009; 54: 43-50.

  54. Wyatt C, Malvestutto C, Coca S, Klotman P, Parikh C. The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008; 22: 1799-807.

  55. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. J Med Virol 2016; 88: 487-97.

  56. Norton B, Park L, McGrath L, Proeschold Bell R, Muir A, Naggie S. Health care utilization in HIV-infected patients: Assessing the burden of hepatitis C virus co-infection. AIDS Patient Care and STDs 2012; 26: 541-5.

  57. Wang C, Wang S, Yao W, Chang T, Chou P. Hepatitis C virus infection and the development of type 2 diabetes in a community- based longitudinal study. Am J Epidemiol 2007; 166: 196-203.

  58. Chien C, Lin C, Hu C, Chang J, Chien R. Clearance of hepatitis C virus improves insulin resistance during and after peginterferon and ribavirin therapy. J Interferon Cytokine Res 2015; 35: 981-9.

  59. Musso G, Gambino R, Tabibian J, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, et al. Association of non –alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis. PLOs One 2014; 11: e1001680.

  60. Hsu C, Kao J, Chao Y, Lin H, Fan Y, Huang C, Tsai P. Interferon- based therapy reduces risk of stroke in chronic hepatitis C patients: a population based cohort study in Taiwan. Aliment Pharmacol Ther 2013; 38: 415-23.

  61. Berenguer J, Rodríguez E, Miralles P, Von Wichmann MA, López-Aldeguer J, Mallolas J, Galindo MJ, et al.; GESIDA HIV/ HCV Cohort Study Group. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients co-infected with HIV and hepatitis C virus. Clin Infect Dis 2012; 55: 728-36.

  62. Hsu Y, Ho H, Huang Y, Wang H, Wu M, Lin J, Wu C. Association between antiviral treatment and extra-hepatic outcomes in patients with hepatitis C virus infection. Gut 2015; 64: 495-503.

  63. Chen Y, Hwang S, Li C, Wu C, Lin L. A Taiwanese nationwide cohort study shows interferon-based therapy for chronic hepatitis C reduces the risk of chronic kidney disease. Medicine 2015; 94: e1334.

  64. Hsu Y, Lin J, Ho H, Kao Y, Huang Y, Hsiao N, Wu M, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology 2014; 59: 1293-302.

  65. Arase Y, Suzuki F, Kawamura Y, Suzuki Y, Kobayashi M, Matsumoto N, Akuta N, et al. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy. Hepatol Res 2011; 41: 946-54.

  66. Leone S, Prosperi M, Costarelli S, Nasta P, Maggiolo F, Di Giambenedetto S, Saracino A, et al. Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV –coinfected patients who achieved sustained virological response. Eur J Clin Microbiol Infect Dis 2016; 35: 1511-20.




2020     |     www.medigraphic.com